Prot# A3921035: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Active Comparator, Multicenter Study to Compare 5 Dose Regimens of CP-690,550 and Adalimumab versus Placebo, Administered for 6 Months in the Treatment of Subjects with Active Rheum

Project: Research project

Project Details

Effective start/end date2/27/082/27/11


  • ICON Clinical Research, LLC (A3921035 // A3921035)
  • Pfizer Inc. (A3921035 // A3921035)